Development and validation of LC–MSMS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma

Citation:
Nouman, E. G., M. A. Al-Ghobashy, and H. M. Lotfy, "Development and validation of LC–MSMS assay for the determination of the prodrug dabigatran etexilate and its active metabolites in human plasma", Journal of Chromatography B, vol. 989, pp. 37 - 45, 2015.

Abstract:

Abstract Dabigatran etexilate (DABE) is a low-molecular-weight prodrug that is converted after oral administration to dabigatran (DAB)—a directly acting oral anticoagulant. In this study, an LC–MSMS assay was developed and validated for the determination of DABE, free \{DAB\} and its equipotent O-glucuronide conjugates in plasma. Owing to the susceptibility of \{DABE\} and \{DAB\} to chemical hydrolysis, cleavage of the O-glucuronide moiety was carried out using β-glucuronidase enzyme. Free and total plasma concentrations of \{DAB\} were determined in incurred plasma samples before and after enzymatic cleavage (50 °C and 3 h), respectively. RP-HPLC separation was carried out using acetonitrile: water (30:70, v/v), adjusted to pH 3.0 using formic acid. Tandem mass spectrometric detection at positive electrospray ionization in the \{MRM\} mode was then employed for the determination of \{DABE\} and DAB. The analysis was carried out within 5.0 min over a linear concentration range of 1.00–600.00 ng/mL for the prodrug and its active metabolite. Validation was carried out according to \{FDA\} guidelines for bioanalytical method. The recoveries were higher than 89.48%, the accuracy was within 98.33–110.12% and the \{RSD\} was below 10% for the studied compounds in both incurred plasma and quality control samples. Results of incurred sample re-analysis and incurred sample stability revealed less than 10% variability. This indicated good assay precision and sufficient stability of target analytes in their real matrix at the employed experimental conditions. The applicability of the assay for therapeutic drug monitoring and the determination of the pharmacokinetic parameters were demonstrated.

Notes:

n/a

Related External Link

Tourism